Monitoring the clinical course of renal transplant patients with hepatitis b and hepatitis c viruses

Objective: The aim of this study is to compare the renal function tests of renal transplantation patients with hepatitis B and hepatitis C viruses and liver enzymes and blood donors in patients with renal transplantation who were not exposed to Hepatitis B and Hepatitis C viruses. Materials and Methods: The study was carried out retrospectively in 872 patient files of renal transplantation performed between 2008 and 2016 at Istanbul Bilim University Sisli Florence Nightingale Hospital General Surgery Department. The effects of hepatitis B and hepatitis C virus on patient and graft survival were investigated. Findings: The patients included in the study were 86.7% of the HBV (+) group, all of the HCV (+) group and 97% of the control group were alive. In hypertension, HBV (+) HCV (+) is significantly higher in the experimental group. In addition, the control group was significantly higher than HBV (+) and HCV (+). When the BUN value of the patients was examined, the HCV (+) group had the highest other groups. HCV (+) group was significantly higher than control group. When the AST value of the patients at 5th year was examined, it was seen that the HCV (+) group had the highest other groups. HCV (+) group was significantly higher than control group. When the current uric acid value of the patients were discharged, it was seen that the HBV (+) group had the highest other groups. HBV (+) group was significantly higher than the mean HCV (+) group. Conclusions: Our findings showed that hepatitis B and hepatitis C virus infection did not affect survival and graft survival in patients with renal transplantation.